Acrux is a differentiated drug delivery specialist targeting global markets and licensee partners.
No-moat Acrux reported interim NPAT of AUD 6.3 million on royalty revenue of AUD 13.7 million, down 35% and 8%, respectively on the previous corresponding period, and broadly as expected given the recent release of Axiron sales data by Eli Lilly on Feb. 1, 2017. Our fair value estimate for Acrux remains steady at AUD 0.40 per share and our very high fair value uncertainty rating is intact.Notwithstanding Axiron which represents the bulk of our fair value estimate, we are encouraged by efforts t...
Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.